ArticleAmerican journal of translational research2026
Shaoyao Gancao decoction for neuropathic pain: a systematic review and meta-analysis of postherpetic neuralgia.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo systematically evaluate the efficacy and safety of Shaoyao Gancao Decoction (SGD) for neuropathic pain (NP), with a focused analysis on postherpetic neuralgia (PHN), the most evidence-rich subtype, and to provide evidence for clinical decision-making.
methodsRandomized controlled trials (RCTs) on SGD for PHN were retrieved from databases up to March 2026. Two reviewers independently screened literature, extracted data, and assessed risk of bias using the Cochrane tool. Meta-analyses were performed using RevMan 5.3, and effect sizes were expressed as odds ratio (OR) or mean difference (MD) with 95% confidence intervals (CIs).
resultsFifteen RCTs involving 1,188 patients with PHN (594 per group) were included. Compared with conventional Western medicine alone, the addition of SGD significantly improved the overall response rate (OR=5.42, 95% CI: 3.40-8.64, P<0.0001), reduced Visual Analogue Scale (VAS) pain score (MD=-1.33, 95% CI: -1.68 to -0.99, P<0.0001), improved Pittsburgh Sleep Quality Index (PSQI) score (MD=-2.23, 95% CI: -2.85 to -1.62, P<0.0001), and lowered the incidence of adverse events (OR=0.34, 95% CI: 0.21-0.56, P<0.0001). Subgroup analyses by treatment duration (14 and 28 days) showed consistent analgesic effects and overall efficacy. Pain Rating Index (PRI) and Present Pain Intensity (PPI) scores were also significantly improved in the SGD group (both P<0.0001). Although high heterogeneity was observed in VAS (I
conclusionCurrent evidence supports SGD as an adjunctive therapy for PHN, with good efficacy and safety. Its potential value for other NP types (such as diabetic peripheral neuropathy, chemotherapy-induced neuropathy) warrants further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.